All In Biotech

Drug Trial Radar · NCT01436968

Phase 3 Study of ProstAtak® Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer

A Randomized Controlled Trial of ProstAtak® as Adjuvant to Up-front Radiation Therapy For Localized Prostate Cancer

Last checked: Nov 19, 2026Latest source record: Oct 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 711 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

711

Planned (sponsor's estimate)

Start

Sep 2011

Primary completion

Aug 2024

Study completion Dec 2030

Sponsor

Lead sponsor
Candel Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Sep 20, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the effectiveness of ProstAtak® immunotherapy in combination with radiation therapy for patients with intermediate-high risk localized prostate cancer. ProstAtak kills tumor cells and stimulates a cancer vaccine effect. Killing tumor cells in an immune stimulatory environment induces the body's immune system to detect and destroy cancer cells. ProstAtak has shown synergy with radiation without added toxicity and lower than expected recurrence rates in previous clinical trials. The hypothesis is that ProstAtak can lead to improvement in the clinical outcome for patients with prostate cancer. Participants will be randomized to the ProstAtak or control arm at a 2:1 ratio. Both arms receive standard external beam radiation therapy. Short-term androgen deprivation therapy may be given but is not required.

Conditions

  • Prostate Cancer

Interventions

  • Aglatimagene besadenovec + valacyclovirBiological

    Patients will receive three courses of ProstAtak® each consisting of aglatimagene besadenovec injection + oral valacyclovir. AdV-tk injection will be delivered to the prostate via trans-rectal ultrasound guided injection as follows: 1. The first injection will be given at least 15 days and not more than 8 weeks before starting radiation. 2. The second injection will be 0-3 days before initiation of radiation therapy. 3. The third injection will be 15-22 days after the 2nd injection. The prodrug, valacyclovir, will be administered at a fixed dose for 14 days after each AdV-tk injection. Standard external beam radiation therapy will be delivered to the prostate. Short-term androgen deprivation therapy (maximum of 6 months) is optional but must be decided before enrollment to allow for stratification.

  • Placebo + valacyclovirBiological

    Patients will receive three courses each consisting of placebo injection + oral valacyclovir. Placebo injection will be delivered to the prostate via trans-rectal ultrasound guided injection as follows: 1. The first injection will be given at least 15 days and not more than 8 weeks before starting radiation. 2. The second injection will be 0-3 days before initiation of radiation therapy. 3. The third injection will be 15-22 days after the 2nd injection. The prodrug, valacyclovir, will be administered at a fixed dose for 14 days after each placebo injection. Standard external beam radiation therapy will be delivered to the prostate. Short-term androgen deprivation therapy (maximum of 6 months) is optional but must be decided before enrollment to allow for stratification.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Disease free survival defined as the time from randomization until the date of the first failure event will be compared for the ProstAtak® arm versus the placebo control arm. The analyses will be based on the intent to treat population.Time frame: Assessed at each visit every 6 months through year 5 until event occurs.

Locations

73 sites in 2 countries. Site status is shown where the registry gives one.

  • Arizona Center for Cancer Care - Gilbert

    Gilbert, Arizona

  • Arizona Urology Specialists

    Glendale, Arizona

  • Arizona Center for Cancer Care - Peoria

    Peoria, Arizona

  • Arizona Center for Cancer Care - Deer Valley

    Phoenix, Arizona

  • Arizona Oncology Services Foundation

    Phoenix, Mesa, Scottsdale, Sedona, Arizona

  • Arizona Center for Cancer Care - Osborne

    Scottsdale, Arizona

  • Arizona Center for Cancer Care - Shea

    Scottsdale, Arizona

  • Arizona Center for Cancer Care - Surprise

    Surprise, Arizona

  • Southern Arizona VA Health Care System

    Tucson, Arizona

  • VA Northern California Health Care System

    Mather, California

  • Precision Radiation Oncology

    Tustin, California

  • Valley View Hospital

    Glenwood Springs, Colorado

  • Colorado Clinical Research

    Lakewood, Colorado

  • Advanced Urology

    Parker, Colorado

  • Sibley Memorial Hospital

    Washington D.C., District of Columbia

  • 21st Century Oncology

    Fort Lauderdale, Florida

  • 21st Century Oncology

    Lakewood Rch, Florida

  • 21st Century Oncology

    Naples, Florida

  • 21st Century Oncology

    Plantation, Florida

  • Clinical Research Center of Florida

    Pompano Beach, Florida

  • James A. Haley Veteran's Hospital

    Tampa, Florida

  • Florida Urology Partners

    Tampa, Florida

  • Jesse Brown VA Medical Center

    Chicago, Illinois

  • The University of Chicago

    Chicago, Illinois

  • Silver Cross Hospital

    New Lenox, Illinois

  • Southeast Louisiana Veterans Health Care System

    New Orleans, Louisiana

  • VA Maryland Health Care System

    Baltimore, Maryland

  • Chesapeake Urology Research Associates

    Baltimore, Maryland

  • The Johns Hopkins University School of Medicine, The Sidney Kimmel Comprehensive Cancer Center

    Baltimore, Maryland

  • Walter Reed National Military Medical Center

    Bethesda, Maryland

  • University of Massachusetts Medical School

    Worcester, Massachusetts

  • Kansas City VA Medical Center

    Kansas City, Missouri

  • Adult & Pediatric Urology, P.C.

    Omaha, Nebraska

  • Sheldon Freedman MD, Ltd.

    Las Vegas, Nevada

  • VA Sierra Nevada Health Care System

    Reno, Nevada

  • New Jersey Urology - Cherry Hill

    Cherry Hill, New Jersey

  • New Jersey Urology - Englewood

    Englewood, New Jersey

  • New Jersey Urology - Milburn

    Millburn, New Jersey

  • New Jersey Urology - Saddle Brook

    Saddle Brook, New Jersey

  • New Jersey Urology - West Orange

    West Orange, New Jersey

Showing 40 of 73 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.